ORBIMED ADVISORS LLC 13D and 13G filings for PMV Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-08-23 4:56 pm Sale |
2023-08-09 | 13D | PMV Pharmaceuticals, Inc. PMVP |
ORBIMED ADVISORS LLC | 6,563,077 13.500% |
-26,253 (-0.40%) |
Filing |
| 2022-04-01 5:06 pm Unchanged |
2022-03-29 | 13D | PMV Pharmaceuticals, Inc. PMVP |
ORBIMED ADVISORS LLC | 6,589,330 14.500% |
0 (Unchanged) |
Filing |
| 2020-10-05 5:23 pm Purchase |
2020-09-25 | 13D | PMV Pharmaceuticals, Inc. PMVP |
ORBIMED ADVISORS LLC | 6,589,330 14.700% |
6,589,330 (New Position) |
Filing |